Economic burden of Pseudomonas aeruginosa infection in patients with cystic fibrosis

Journal of Medical Economics

Volumn 15, Issue 2, 2012, Pages 219-224

  Sansgiry, Sujit S ^a   Joish, Vijay N ^b   Boklage, Susan ^b   Goyal, Ravi K ^c   Chopra, Pooja ^d   Sethi, Sanjay ^e  

^a UNIVERSITY OF HOUSTON   (United States)

^b IMS Health   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d ANALYSIS GROUP   (United States)

^e UNIVERSITY AT BUFFALO   (United States)

Author keywords

Cystic fibrosis; Healthcare costs; Healthcare utilization; Pseudomonas aeruginosa

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CHILD; CONSULTATION; CYSTIC FIBROSIS; DATA BASE; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL CARE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; OUTPATIENT CARE; PRESCRIPTION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; UNITED STATES;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; CYSTIC FIBROSIS; DATABASES, FACTUAL; FEMALE; HEALTH EXPENDITURES; HUMANS; INFANT; MALE; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84858122247     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.638954     Document Type: Article

References (19)

1. Strausbaugh SD, Davis PB. Cystic fibrosis: a review of epidemiology and pathobiology. Clin Chest Med 2007;28:279-88 (Pubitemid 46661880)
2. Cystic Fibrosis Foundation Patient Registry. 2009 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation Patient Registry, 2009
3. Elphick HE, Smyth RL. Infections in patients with cystic fibrosis: effects of a longer survival. The Microbe-Host Interface in Respiratory Tract Infections. England: Horizon Scientific Press Ltd, 2004
4. Govan J, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Molr Biol Rev 1996;60:539
5. Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91-100 (Pubitemid 34809519)
6. Deretic V, Schurr M, Boucher J, et al. Conversion of Pseudomonas aeruginosa to mucoidy in cystic fibrosis: environmental stress and regulation of bacterial virulence by alternative sigma factors. J Bacteriol 1994;176:2773
7. Nixon GM, Armstrong DS, Carzino R, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001; 138:699-704 (Pubitemid 32417671)
8. Winnie GB, Cowan RG. Respiratory tract colonization with Pseudomonas aeruginosa in cystic fibrosis: correlations between anti Pseudomonas aeruginosa antibody levels and pulmonary function. Pediatr Pulmonol 1991; 10:92-100
9. Britto MT, Kotagal UR, Hornung RW, et al. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002;121:64
10. Jones AM, Dodd ME, Morris J, et al. Clinical outcome for cystic fibrosis patients infected with transmissible Pseudomonas aeruginosa: an 8-year prospective study. Chest 2010;137:1405
11. Ouyang L, Grosse SD, Amendah DD, et al. Healthcare expenditures for privately insured people with cystic fibrosis. Pediatr Pulmonol 2009;44:989-96
12. Briggs EC, Nguyen T, Wall MC, et al. Oral antimicrobial use in outpatient cystic fibrosis pulmonary exacerbation management; a single center experience. Clin Respir J 2011: published online 9 August 2011, doi:10.1111/j.1752-699X. 2011.00246.x13.
13. Lee T. Eradication of early Pseudomonas infection in cystic fibrosis. Chron Respir Dis 2009;6:99
14. Taccetti G, Campana S, Festini F, et al. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005; 26:458
15. Moss RB. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest 2001;120(3 Suppl):107S
16. Waknine Y. FDA approves inhaled aztreonam for cystic fibrosis. Medscape Today; 2010. Available at www.medscape.com/viewarticle/717553. [Last accessed 19 September 2011]
17. Wolter J, Seeney S, Bell S, et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002;57:212
18. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. JAMA 2003;290:1749
19. U.S. Food and Drug Administration approves Cayston(R) for the improvement of respiratory symptoms in cystic fibrosis patients with pseudomonas aeruginosa. Gilead Press Release. Available at: http://www.gilead.com/pr- 1393831. Accessed October 30, 2011